Insta
Eisai’s Lecanemab Drug For Alzheimer’s Gets Breakthrough Therapy Designation From US FDA
Swarajya Staff
Jun 24, 2021, 02:03 PM | Updated 02:03 PM IST
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
Japanese pharmaceutical company Eisai Co and partner Biogen Inc have acquired the breakthrough therapy designation from the US Food and Drug Administration (FDA) for its experimental therapy lecanemab for patients suffering from early Alzheimer’s.
This particular drug reportedly tends to work similarly to Biogen’s Aduhelm that had attained approval in June itself.
Lecanemab separates sticky protein deposits named amyloid beta from a patient’s brain in the initial stages of Alzheimer’s. This cuts down the possible impact of loss of memory and an individual’s overall inability to look after oneself.
Eisai had rounded up the enrollment process in March in an integral year-and-long assessment of lecanemab in symptomatic patients of early Alzheimer’s.
Moreover, the drug is also being put through a large trial that will be carried out on asymptomatic individuals who show evidence of amyloid in their brains, Indian Express reports.
The breakthrough therapy designation is a program of the FDA that aims to fast-track the development and assessment of medicines for conditions that are serious or threatening to life.
This designation paves the way for further intensive guidance on a development initiative that is efficient and also for eligibility for rolling review and a prospective priority review too.
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.